Editorial

Lighting the match
January 2019 issue editorial by Thierry Heles, editor, Global University Venturing
Big deal: Stanford-StartX Fund reaches the end
The Stanford University-backed fund will halt new investments from July, seemingly as the accelerator reaches financial stability but in the midst of a legal battle.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
The only way has always been up
November issue editorial by Thierry Heles, editor, Global University Venturing
Everything ventured, everything gained
Introducing the Global University Venturing Powerlist 2018
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
When the comic gets serious
October issue editorial by Thierry Heles, editor, Global University Venturing
UCL Technology Fund: an unparalleled approach to commercialisation
Editor Thierry Heles sits down with David Grimm (pictured), manager of the UCL Technology Fund, to find out what makes the fund unique among its UK and international peers.

Other News

Editorial: For the good of investors
As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.
Stacking the odds in universities’ favour
The GUV September issue editorial by Thierry Heles.
Europe’s most important budget
Editor-in-chief James Mawson takes an in-depth look at what the Horizon Europe budget needs to achieve.
Editorial: The current and future state of UVFs
Editor-in-chief James Mawson takes a look at assumed problems around university IP and considers the opportunities of university venture funds ahead of a report by Hermann Hauser.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.

Editor's Picks

Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Everything ventured, everything gained
Introducing the Global University Venturing Powerlist 2018
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
UCL Technology Fund: an unparalleled approach to commercialisation
Editor Thierry Heles sits down with David Grimm (pictured), manager of the UCL Technology Fund, to find out what makes the fund unique among its UK and international peers.
test reg

Login